The European Medicines Agency (EMA) has established a formal cluster on biosimilar products with the US Food and Drug Administration (FDA), Health Canada (HC), Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Swissmedic, according to terms of reference dated 3 March 2026 and published on 17 July 2026. The cluster aims to achieve a common understanding of each agency's regulatory approaches to biosimilar product development and to provide a forum for confidential exchange of draft documents, policies and scientific information supporting decision-making.
The cluster will address multidisciplinary aspects of biosimilar development, evaluation and post-marketing, including quality, efficacy and safety. Topics for discussion include regulatory pathways, analytical and functional comparability, clinical study design, pharmacokinetics, immunogenicity, product naming, labelling and post-marketing monitoring. Participating agencies can share marketing authorisation applications and related assessment reports for both initial and post-marketing phases.
Membership includes staff from EMA's Pharmaceutical Quality Office, Clinical Therapeutic Areas Offices and Scientific Advice, as well as EU assessors from the Biosimilar Medicinal Products Working Party (BMWP). FDA participants will come from the Center for Drug Evaluation and Research (CDER), including the Office of Therapeutic Biologics and Biosimilars. Health Canada will involve colleagues from the Biologic and Radiopharmaceutical Drugs Directorate (BRDD) and the Marketed Health Products Directorate (MHPD). PMDA and Swissmedic will each designate relevant experts.
The cluster plans to hold teleconferences twice per year, each lasting up to two hours, with ad-hoc meetings possible for pressing issues. Meetings will be chaired by agencies on a rotating basis, with high-level minutes and action lists circulated within three weeks. The EMA's BMWP secretariat will provide secretariat support.
The cluster is expected to benefit biosimilar developers by promoting regulatory convergence and potentially reducing duplication of clinical data requirements across jurisdictions. For patients, harmonised standards could accelerate access to affordable biosimilars. National competent authorities in EU member states may see increased alignment with international peers, though the cluster's work remains confidential and does not create binding obligations. The pharmaceutical industry gains a clearer pathway for global biosimilar development, but may face additional scrutiny as regulators share assessment reports and post-marketing data.
No prior coverage of this initiative exists in the available record.